Ibrahim El-Battrawy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2461066/publications.pdf

Version: 2024-02-01

172457 233421 2,953 186 29 45 citations g-index h-index papers 191 191 191 2833 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Long-Term Prognosis of Patients With Takotsubo Syndrome. Journal of the American College of Cardiology, 2018, 72, 874-882.	2.8	224
2	Lipopolysaccharides induced inflammatory responses and electrophysiological dysfunctions in human-induced pluripotent stem cell derived cardiomyocytes. Scientific Reports, 2017, 7, 2935.	3.3	111
3	Modeling Short QT Syndrome Using Humanâ€Induced Pluripotent Stem Cell–Derived Cardiomyocytes. Journal of the American Heart Association, 2018, 7, .	3.7	88
4	Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry. Journal of Nephrology, 2020, 33, 737-745.	2.0	81
5	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. European Heart Journal, 2019, 40, 2142-2151.	2.2	7 9
6	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. Circulation, 2019, 139, 413-415.	1.6	75
7	Incidence and Clinical Impact of Recurrent Takotsubo Syndrome: Results From the GEIST Registry. Journal of the American Heart Association, 2019, 8, e010753.	3.7	74
8	Prevalence of cancer in Takotsubo cardiomyopathy: Short and long-term outcome. International Journal of Cardiology, 2017, 238, 159-165.	1.7	62
9	Prevalence of malignant arrhythmia and sudden cardiac death in takotsubo syndrome and its management. Europace, 2018, 20, 843-850.	1.7	61
10	Ion Channel Expression and Characterization in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Stem Cells International, 2018, 2018, 1-14.	2.5	60
11	Assessment of the German and Italian Stress Cardiomyopathy Score for Risk Stratification for In-hospital Complications in Patients With Takotsubo Syndrome. JAMA Cardiology, 2019, 4, 892.	6.1	60
12	Estradiol protection against toxic effects of catecholamine on electrical properties in human-induced pluripotent stem cell derived cardiomyocytes. International Journal of Cardiology, 2018, 254, 195-202.	1.7	55
13	Impact of concomitant atrial fibrillation on the prognosis of Takotsubo cardiomyopathy. Europace, 2017, 19, 1288-1292.	1.7	54
14	Prevalence and Prognostic Impact of Diabetes in Takotsubo Syndrome: Insights From the International, Multicenter GEIST Registry. Diabetes Care, 2018, 41, 1084-1088.	8.6	53
15	Electrical dysfunctions in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with an arrhythmogenic right ventricular cardiomyopathy. Europace, 2018, 20, f46-f56.	1.7	50
16	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. European Heart Journal, 2020, 41, 3255-3268.	2.2	49
17	Intronic CRISPR Repair in a Preclinical Model of Noonan Syndrome–Associated Cardiomyopathy. Circulation, 2020, 142, 1059-1076.	1.6	43
18	Age-Related Variations in Takotsubo Syndrome. Journal of the American College of Cardiology, 2020, 75, 1869-1877.	2.8	42

#	Article	IF	CITATIONS
19	Abnormal thyroid function is common in takotsubo syndrome and depends on two distinct mechanisms: results of a multicentre observational study. Journal of Internal Medicine, 2021, 289, 675-687.	6.0	42
20	Characteristics and long-term outcome of right ventricular involvement in Takotsubo cardiomyopathy. International Journal of Cardiology, 2016, 220, 371-375.	1.7	40
21	Ion Channel Dysfunctions in Dilated Cardiomyopathy in Limb-Girdle Muscular Dystrophy. Circulation Genomic and Precision Medicine, 2018, 11, e001893.	3.6	40
22	Phrenic Nerve Injury During Cryoballoon-Based Pulmonary Vein Isolation: Results of the Worldwide YETI Registry. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010516.	4.8	39
23	Takotsubo Syndrome and Embolic Events. Heart Failure Clinics, 2016, 12, 543-550.	2.1	36
24	Prevalence, Clinical Characteristics, and Predictors of Patients with Thromboembolic Events in Takotsubo Cardiomyopathy. Clinical Medicine Insights: Cardiology, 2016, 10, CMC.S38151.	1.8	35
25	Longâ€Term Followâ€Up of Patients With Short QT Syndrome: Clinical Profile and Outcome. Journal of the American Heart Association, 2018, 7, e010073.	3.7	35
26	Clinical outcomes associated with catecholamine use in patients diagnosed with Takotsubo cardiomyopathy. BMC Cardiovascular Disorders, 2018, 18, 54.	1.7	35
27	Prevalence, management, and outcome of adverse rhythm disorders in takotsubo syndrome: insights from the international multicenter GEIST registry. Heart Failure Reviews, 2020, 25, 505-511.	3.9	35
28	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 279-287.	2.4	34
29	Impact of Sacubitril/Valsartan on the Long-Term Incidence of Ventricular Arrhythmias in Chronic Heart Failure Patients. Journal of Clinical Medicine, 2019, 8, 1582.	2.4	33
30	A cellular model of Brugada syndrome with SCN10A variants using human-induced pluripotent stem cell-derived cardiomyocytes. Europace, 2019, 21, 1410-1421.	1.7	33
31	Gender Differences in Takotsubo Syndrome. Journal of the American College of Cardiology, 2022, 79, 2085-2093.	2.8	33
32	- LAA Occluder View for post-implantation Evaluation (LOVE) - standardized imaging proposal evaluating implanted left atrial appendage occlusion devices by cardiac computed tomography. BMC Medical Imaging, 2016, 16, 25.	2.7	29
33	Studying Brugada Syndrome With an SCN1B Variants in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Frontiers in Cell and Developmental Biology, 2019, 7, 261.	3.7	29
34	Hyperthermia Influences the Effects of Sodium Channel Blocking Drugs in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. PLoS ONE, 2016, 11, e0166143.	2.5	28
35	Type 2 diabetes is independently associated with all-causeÂmortality secondary to ventricular tachyarrhythmias. Cardiovascular Diabetology, 2018, 17, 125.	6.8	27
36	Impact of aspirin on takotsubo syndrome: a propensity scoreâ€based analysis of the InterTAK Registry. European Journal of Heart Failure, 2020, 22, 330-337.	7.1	24

#	Article	IF	CITATIONS
37	Takotsubo Syndrome: Translational Implications and Pathomechanisms. International Journal of Molecular Sciences, 2022, 23, 1951.	4.1	23
38	Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction. Annals of Laboratory Medicine, 2018, 38, 306-315.	2.5	22
39	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry. Internal and Emergency Medicine, 2021, 16, 957-966.	2.0	22
40	Comparison and Outcome Analysis of Patients with Takotsubo Cardiomyopathy Triggered by Emotional Stress or Physical Stress. Frontiers in Psychology, 2017, 8, 527.	2.1	21
41	Implantable cardioverterâ€defibrillator in Brugada syndrome: Longâ€ŧerm followâ€up. Clinical Cardiology, 2019, 42, 958-965.	1.8	21
42	Drug Testing in Humanâ€Induced Pluripotent Stem Cell–Derived Cardiomyocytes From a Patient With Short <scp>QT</scp> Syndrome Type 1. Clinical Pharmacology and Therapeutics, 2019, 106, 642-651.	4.7	21
43	Clinical and echocardiographic analysis of patients suffering from recurrent takotsubo cardiomyopathy. Journal of Geriatric Cardiology, 2016, 13, 888-893.	0.2	21
44	Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting. BMC Cardiovascular Disorders, 2018, 18, 52.	1.7	20
45	Prediction of short―and longâ€ŧerm mortality in takotsubo syndrome: the InterTAK Prognostic Score. European Journal of Heart Failure, 2019, 21, 1469-1472.	7.1	20
46	Long-term follow-up of implantable cardioverter-defibrillators in Short QT syndrome. Clinical Research in Cardiology, 2019, 108, 1140-1146.	3.3	20
47	Incidence, determinants and prognostic relevance of dyspnea at admission in patients with Takotsubo syndrome: results from the international multicenter GEIST registry. Scientific Reports, 2020, 10, 13603.	3.3	20
48	Does there exist an obesity paradox in COVID-19? Insights of the international HOPE-COVID-19-registry. Obesity Research and Clinical Practice, 2021, 15, 275-280.	1.8	20
49	Impact of left atrial appendage morphology on thrombus formation after successful left atrial appendage occlusion: Assessment with cardiac-computed-tomography. Scientific Reports, 2018, 8, 1670.	3.3	19
50	Comparison and outcome analysis of patients with apical and non-apical takotsubo cardiomyopathy. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 797-802.	0.5	18
51	Impact of Antiarrhythmic Drugs on the Outcome of Short QT Syndrome. Frontiers in Pharmacology, 2019, 10, 771.	3.5	18
52	Ezetimibe inhibits platelet activation and uPAR expression on endothelial cells. International Journal of Cardiology, 2017, 227, 858-862.	1.7	16
53	Beta-Blockers and ACE Inhibitors Are Associated with Improved Survival Secondary to Ventricular Tachyarrhythmia. Cardiovascular Drugs and Therapy, 2018, 32, 353-363.	2.6	16
54	Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Future Cardiology, 2020, 16, 227-236.	1.2	16

#	Article	IF	CITATIONS
55	Incidence and Clinical Impact of Right Ventricular Involvement (Biventricular Ballooning) in Takotsubo Syndrome. Chest, 2021, 160, 1433-1441.	0.8	16
56	Coincidental coronary artery disease impairs outcome in patients with takotsubo cardiomyopathy. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 483-488.	0.5	16
57	Longâ€ŧerm results of combined cardiac contractility modulation and subcutaneous defibrillator therapy in patients with heart failure and reduced ejection fraction. Clinical Cardiology, 2018, 41, 518-524.	1.8	15
58	Nucleoside Diphosphate Kinase B Contributes to Arrhythmogenesis in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Arrhythmogenic Right Ventricular Cardiomyopathy. Journal of Clinical Medicine, 2020, 9, 486.	2.4	15
59	Biomarkers in Cardiomyopathies and Prediction of Sudden Cardiac Death. Current Pharmaceutical Biotechnology, 2017, 18, 472-481.	1.6	15
60	Impact and management of left ventricular function on the prognosis of Takotsubo syndrome. European Journal of Clinical Investigation, 2017, 47, 477-485.	3.4	14
61	Arrhythmic events in Brugada syndrome patients induced by fever. Annals of Noninvasive Electrocardiology, 2020, 25, e12723.	1.1	14
62	COVIDâ€19 and the impact of arterial hypertensionâ€"An analysis of the international HOPE COVIDâ€19 Registry (Italyâ€Spainâ€Germany). European Journal of Clinical Investigation, 2021, 51, e13582.	3.4	14
63	Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score. Frontiers in Medicine, 2021, 8, 728102.	2.6	14
64	Triple head-to-head comparison of fibrotic biomarkers galectin-3, osteopontin and gremlin-1 for long-term prognosis in suspected and proven acute heart failure patients. International Journal of Cardiology, 2016, 203, 398-406.	1.7	13
65	Interaction between the heart and the brain in transient global amnesia. Journal of Neurology, 2019, 266, 3048-3057.	3.6	13
66	Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest. Clinical Research in Cardiology, 2019, 108, 669-682.	3.3	13
67	The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up. Journal of Clinical Medicine, 2020, 9, 893.	2.4	13
68	TRPV1 activation and internalization is part of the LPS-induced inflammation in human iPSC-derived cardiomyocytes. Scientific Reports, 2021, 11, 14689.	3.3	13
69	Left atrial appendage morphology, echocardiographic characterization, procedural data and in-hospital outcome of patients receiving left atrial appendage occlusion device implantation: a prospective observational study. BMC Cardiovascular Disorders, 2016, 16, 25.	1.7	12
70	Takotsubo syndrome and cardiac implantable electronic device therapy. Scientific Reports, 2019, 9, 16559.	3.3	12
71	Short- and Long-Term Incidence of Thromboembolic Events in Takotsubo Syndrome as Compared With Acute Coronary Syndrome. Angiology, 2019, 70, 838-843.	1.8	12
72	Sex-differences in short QT syndrome: A systematic literature review and pooled analysis. European Journal of Preventive Cardiology, 2020, 27, 1335-1338.	1.8	12

#	Article	IF	Citations
73	Differences in Short QT Syndrome Subtypes: A Systematic Literature Review and Pooled Analysis. Frontiers in Genetics, 2019, 10, 1312.	2.3	12
74	Reduced Na $\langle \sup \rangle + \langle \sup \rangle$ Current in Native Cardiomyocytes of a Brugada Syndrome Patient Associated With \hat{l}^2 -2-Syntrophin Mutation. Circulation Genomic and Precision Medicine, 2018, 11, e002263.	3.6	11
75	Alpha 1-adrenoceptor signalling contributes to toxic effects of catecholamine on electrical properties in cardiomyocytes. Europace, 2021, 23, 1137-1148.	1.7	11
76	Deciphering the pathogenic role of a variant with uncertain significance for short QT and Brugada syndromes using geneâ€edited humanâ€induced pluripotent stem cellâ€derived cardiomyocytes and preclinical drug screening. Clinical and Translational Medicine, 2021, 11, e646.	4.0	11
77	Procedural success and intraâ€hospital outcome related to left atrial appendage morphology in patients that receive an interventional left atrial appendage closure. Clinical Cardiology, 2017, 40, 566-574.	1.8	10
78	Occlusion of left atrial appendage affects metabolomic profile: focus on glycolysis, tricarboxylic acid and urea metabolism. Metabolomics, 2017, 13, 127.	3.0	10
79	The Risk for Sudden Cardiac Death and Effect of Treatment With Sacubitril/Valsartan inÂHeartÂFailure. JACC: Heart Failure, 2019, 7, 999.	4.1	10
80	lonic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1 . Frontiers in Pharmacology, 2020, 11 , 554422 .	3.5	10
81	Different genotypes of Brugada syndrome may present different clinical phenotypes: electrophysiology from bench to bedside. European Heart Journal, 2021, 42, 1270-1272.	2.2	10
82	Preclinical short QT syndrome models: studying the phenotype and drug-screening. Europace, 2022, 24, 481-493.	1.7	10
83	Clinical Outcomes in Patients with Ischemic versus Non-Ischemic Cardiomyopathy after Angiotensin-Neprilysin Inhibition Therapy. Journal of Clinical Medicine, 2021, 10, 4989.	2.4	10
84	Brugada Syndrome: Different Experimental Models and the Role of Human Cardiomyocytes From Induced Pluripotent Stem Cells. Journal of the American Heart Association, 2022, 11, e024410.	3.7	10
85	Incidence and Prognostic Relevance of Cardiopulmonary Failure in Takotsubo Cardiomyopathy. Scientific Reports, 2017, 7, 14673.	3.3	9
86	Prognostic Impact of Percutaneous Coronary Intervention of Chronic Total Occlusion in Acute and Periprocedural Myocardial Infarction. Journal of Clinical Medicine, 2021, 10, 258.	2.4	9
87	Comparison of the prognosis and outcome of heart failure with reduced ejection fraction patients treated with sacubitril/valsartan according to age. Future Cardiology, 2021, 17, 1131-1142.	1.2	9
88	Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study. American Journal of Cardiovascular Drugs, 2022, 22, 535-544.	2.2	9
89	Long term outcome of patients suffering from cancer and Takotsubo syndrome or myocardial infarction. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 473-481.	0.5	8
90	Shortâ€ŧerm and longâ€ŧerm incidence of stroke in Takotsubo syndrome. ESC Heart Failure, 2018, 5, 1191-1194.	3.1	8

#	Article	IF	Citations
91	Gender-based comparison of takotsubo syndrome versus myocardial infarction. QJM - Monthly Journal of the Association of Physicians, 2019, 112, 355-362.	0.5	8
92	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. ESC Heart Failure, 2021, 8, 1924-1932.	3.1	8
93	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. Clinical Research in Cardiology, 2022, 111, 186-196.	3.3	8
94	Predictors of mortality in Takotsubo cardiomyopathy. European Journal of Heart Failure, 2017, 19, 158-158.	7.1	7
95	Prognostic impact of beta-blocker compared to combined amiodarone therapy secondary to ventricular tachyarrhythmias. International Journal of Cardiology, 2019, 277, 118-124.	1.7	7
96	Improved Outcome of Cardiogenic Shock Triggered by Takotsubo Syndrome Compared With Myocardial Infarction. Canadian Journal of Cardiology, 2020, 36, 860-867.	1.7	7
97	Biomarker evaluation as a potential cause of gender differences in obesity paradox among patients with STEMI. Cardiovascular Revascularization Medicine, 2016, 17, 88-94.	0.8	6
98	The link between atrial fibrillation and hereditary channelopathies. Europace, 2018, 20, 1872-1872.	1.7	6
99	Atrial Fibrillation Is Associated with Increased Mortality in Patients Presenting with Ventricular Tachyarrhythmias. Scientific Reports, 2019, 9, 14291.	3.3	6
100	Statin therapy is associated with improved survival in patients with ventricular tachyarrhythmias. Lipids in Health and Disease, 2019, 18, 119.	3.0	6
101	Serum of patients with acute myocardial infarction prevents inflammation in iPSC-cardiomyocytes. Scientific Reports, 2019, 9, 5651.	3.3	6
102	The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome. Frontiers in Pharmacology, 2020, 11, 681.	3.5	6
103	Long-Term Follow-Up of Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. Journal of Clinical Medicine, 2020, 9, 903.	2.4	6
104	Age related differences and outcome of patients with Takotsubo syndrome. Journal of Geriatric Cardiology, 2017, 14, 632-638.	0.2	6
105	Pooled Analysis of Complications with Transvenous ICD Compared to Subcutaneous ICD in Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. Journal of Personalized Medicine, 2022, 12, 536.	2.5	6
106	Thalassaemia is paradoxically associated with a reduced risk of inâ€hospital complications and mortality in COVIDâ€19: Data from an international registry. Journal of Cellular and Molecular Medicine, 2022, 26, 2520-2528.	3.6	6
107	Design and Rationale of the Femoral Closure versus Radial Compression Devices Related to Percutaneous Coronary Interventions (FERARI) Study. Clinical Medicine Insights: Cardiology, 2015, 9, CMC.S31932.	1.8	5
108	Takotsubo Cardiomyopathy: Another Form of Cardiorenal Syndrome. Angiology, 2018, 69, 130-135.	1.8	5

#	Article	IF	CITATIONS
109	Bedside implantation of a new temporary vena cava inferior filter - Safety and efficacy results of the European ANGEL-Registry. Journal of Critical Care, 2018, 44, 39-44.	2.2	5
110	COPD increases cardiac mortality in patients presenting with ventricular tachyarrhythmias and aborted cardiac arrest. Respiratory Medicine, 2018, 145, 153-160.	2.9	5
111	Protective effect of acquired long QT syndrome in Takotsubo syndrome. Internal Medicine Journal, 2019, 49, 770-776.	0.8	5
112	Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. Frontiers in Pharmacology, 2021, 12, 675003.	3.5	5
113	Real life experience with the wearable cardioverter-defibrillator in an international multicenter Registry. Scientific Reports, 2022, 12, 3203.	3.3	5
114	Catecholamine in takotsubo syndrome. International Journal of Cardiology, 2017, 233, 97.	1.7	4
115	Clinical outcomes of femoral closure compared to radial compression devices following percutaneous coronary intervention: the FERARI study. Heart and Vessels, 2017, 32, 520-530.	1.2	4
116	Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data. Medicina ClÃnica, 2021, 157, 318-324.	0.6	4
117	Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data. Medicina ClÃnica (English Edition), 2021, 157, 318-324.	0.2	4
118	Comparison of the Outcome of Patients Protected by the Wearable Cardioverter Defibrillator (WCD) for <90 Wear Days <i>versus</i> ≥90 Wear Days. In Vivo, 2020, 34, 3601-3610.	1.3	4
119	Dopamine D1/D5 Receptor Signaling Is Involved in Arrhythmogenesis in the Setting of Takotsubo Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 777463.	2.4	4
120	Solid Right Ventricular Compression by Intraventricular Septum-Hematoma Induced after Percutaneous Coronary Intervention. Case Reports in Cardiology, 2016, 2016, 1-4.	0.2	3
121	Association of a congenital long QT syndrome type 1 with Takotsubo cardiomyopathy. Clinical Case Reports (discontinued), 2016, 4, 789-792.	0.5	3
122	Hormone Status Correlates With Incidence of Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2312-2313.	2.8	3
123	Atrial fibrillation as a risk factor for worse outcome in acute coronary syndrome. International Journal of Cardiology, 2017, 246, 53.	1.7	3
124	Endothelial dysfunction in takotsubo syndrome. International Journal of Cardiology, 2017, 234, 101.	1.7	3
125	Myocardial Dysfunction Following Brain Death. Journal of the American College of Cardiology, 2018, 71, 368.	2.8	3
126	Risk stratification in Takotsubo syndrome: a role of mitral annular plane systolic excursion. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 231-236.	0.5	3

#	Article	IF	Citations
127	Impact of ST-segment elevation on the outcome of Takotsubo syndrome. Therapeutics and Clinical Risk Management, 2019, Volume 15, 251-258.	2.0	3
128	Impact of Tâ€inversion on the outcome of Takotsubo syndrome as compared to acute coronary syndrome. European Journal of Clinical Investigation, 2019, 49, e13078.	3.4	3
129	Comparable survival in ischemic and nonischemic cardiomyopathy secondary to ventricular tachyarrhythmias and aborted cardiac arrest. Coronary Artery Disease, 2019, 30, 303-311.	0.7	3
130	Male sex increases mortality in ventricular tachyarrhythmias. Internal Medicine Journal, 2019, 49, 711-721.	0.8	3
131	Clinical Profile and Long-Term Follow-Up of Children with Brugada Syndrome. Pediatric Cardiology, 2020, 41, 290-296.	1.3	3
132	Electrical storm reveals worse prognosis compared to myocardial infarction complicated by ventricular tachyarrhythmias in ICD recipients. Heart and Vessels, 2021, 36, 1701-1711.	1.2	3
133	Impact of sacubitril/valsartan on cardiac arrest event rate. Letter regarding the article †Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISEâ€MI): design and baseline characteristics'. European Journal of Heart Failure, 2022, 24. 1324-1324.	7.1	3
134	Regulation of Ion Channel Function in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes by Cancer Cell Secretion Through DNA Methylation. Frontiers in Cardiovascular Medicine, 2022, 9, 839104.	2.4	3
135	Letter by El-Battrawy et al Regarding Article, "The Brugada Syndrome Susceptibility Gene HEY2 Modulates Cardiac Transmural Ion Channel Patterning and Electrical Heterogeneity― Circulation Research, 2017, 121, e20.	4.5	2
136	P3822Esophageal cancer related gene-4 affects multiple ion channel expression in human-induced stem cell-derived cardiomyocytes. European Heart Journal, 2018, 39, .	2.2	2
137	Response to Comment on Stiermaier et al. Prevalence and Prognostic Impact of Diabetes in Takotsubo Syndrome: Insights From the International, Multicenter GEIST Registry. Diabetes Care 2018;41:1084à€"1088. Diabetes Care, 2018, 41, e122-e122.	8.6	2
138	Association Between Mortality and Left Ventricular Ejection Fraction in Patients With Takotsubo Syndrome <i>Versus</i> Acute Coronary Syndrome. In Vivo, 2020, 34, 3639-3648.	1.3	2
139	The current evidence of Takotsubo syndrome. Future Cardiology, 2021, 17, 1293-1295.	1.2	2
140	Risk factor paradox: No prognostic impact of arterial hypertension and smoking in patients with ventricular tachyarrhythmias. Cardiology Journal, 2020, 27, 715-725.	1.2	2
141	Abnormal Cardiac Repolarization in Thyroid Diseases: Results of an Observational Study. Frontiers in Cardiovascular Medicine, 2021, 8, 738517.	2.4	2
142	Antiarrhythmic Effects of Vernakalant in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Short QT Syndrome Type 1. Journal of Cardiovascular Development and Disease, 2022, 9, 112.	1.6	2
143	Lipopolysaccharide Modifies Sodium Current Kinetics through ROS and PKC Signalling in Induced Pluripotent Stem-Derived Cardiomyocytes from Brugada Syndrome Patient. Journal of Cardiovascular Development and Disease, 2022, 9, 119.	1.6	2
144	New Oral Anticoagulation after Heart Valve Replacement. Cardiovascular $\&$ Hematological Disorders Drug Targets, 2015, 15, 106-109.	0.7	1

#	Article	IF	CITATIONS
145	Reply to: Diabetes mellitus and Takotsubo syndrome: Dissecting the paradox. International Journal of Cardiology, 2017, 229, 135.	1.7	1
146	Letter by El-Battrawy et al Regarding Article, "Takotsubo-Like Myocardial Dysfunction in Ischemic Stroke: A Hospital-Based Registry and Systematic Literature Reviewâ€. Stroke, 2017, 48, e72.	2.0	1
147	Î ² -Blockers and Outcome After Acute MyocardialÂInfarction. Journal of the American College of Cardiology, 2017, 70, 1685.	2.8	1
148	Feasibility of drugs in Brugada syndrome. Europace, 2018, 20, f137-f137.	1.7	1
149	Psychiatric Disease Among Patients With Takotsubo Syndrome. Psychosomatics, 2018, 59, 101-102.	2.5	1
150	Atrial fibrillation impacts the outcome in Takotsubo syndrome. International Journal of Cardiology, 2018, 251, 57.	1.7	1
151	The pathophysiology of arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Europace, 2018, 20, f138-f138.	1.7	1
152	Cardiac voltage-sodium channel mutations association with primary electrical diseases. Europace, 2018, 20, 1707-1707.	1.7	1
153	Predictors of thromboembolic events in Takotsubo syndrome. European Journal of Heart Failure, 2019, 21, 1482-1482.	7.1	1
154	Neurocardiac Injury in Patients With Subarachnoid Hemorrhage. JACC: Cardiovascular Imaging, 2019, 12, 2094-2095.	5.3	1
155	â€~Mature' resting membrane potentials in hiPSC-CMs: fact or artefact?—Authors' reply. Europace, 201° 21, 1928-1929.	9,1.7	1
156	Genotype–phenotype association in patients with SCN4A mutation. Lancet, The, 2019, 393, 2301.	13.7	1
157	Cardiac contractility modulation efficacy: is there a difference between ischemic vs. non-ischemic patients?. European Heart Journal, 2020, 41, .	2.2	1
158	Expression of Inflammation-related Intercellular Adhesion Molecules in Cardiomyocytes In Vitro and Modulation by Pro-inflammatory Agents. In Vivo, 2016, 30, 213-7.	1.3	1
159	A Case Series of Concomitant Cardiac Electrical Disease among Takotsubo Syndrome Patients and Literature Review. Journal of Cardiovascular Development and Disease, 2022, 9, 79.	1.6	1
160	Impact of stress on Takotsubo syndrome. International Journal of Cardiology, 2017, 242, 33.	1.7	0
161	Dissecting the diagnosis of biventricular myocarditis. International Journal of Cardiology, 2017, 242, 43.	1.7	O
162	Reply to "Cancer and Takotsubo Cardiomyopathy: More questions than answers". International Journal of Cardiology, 2017, 242, 14.	1.7	0

#	Article	IF	CITATIONS
163	Ballooning Pattern and Related Outcome in Takotsubo Syndrome. American Journal of Cardiology, 2017, 120, e63.	1.6	0
164	Sodium channel blockers in Brugada syndrome. Europace, 2018, 20, f139-f139.	1.7	0
165	Letter by El-Battrawy et al Regarding Article, "The Effects of Public Access Defibrillation on Survival After Out-of-Hospital Cardiac Arrest: A Systematic Review of Observational Studies― Circulation, 2018, 137, 1646-1647.	1.6	0
166	P3818Kinetic changes in a mutant hERG channel (N588K) in in human-induced pluripotent stem cell-derived cardiomyocytes. European Heart Journal, 2018, 39, .	2.2	0
167	P3821Lipopolysaccharides inhibited T-type calcium channels in human-induced pluripotent stem cell-derived cardiomyocytes. European Heart Journal, 2018, 39, .	2.2	0
168	P2870Nucleoside diphosphate kinase B increases the pacemaker activity in human induced pluripotent stem cell-derived cardiomyocytes. European Heart Journal, 2018, 39, .	2.2	0
169	P2866Drug-testing using human-induced pluripotent stem cell-derived cardiomyocytes from a patient with short QT syndrome. European Heart Journal, 2018, 39, .	2.2	0
170	Cognitive Deficit in Heart Failure Patients. JACC: Heart Failure, 2018, 6, 888-889.	4.1	0
171	Letter by El-Battrawy et al Regarding Article, "Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA ₂ DS ₂ -VASc-VA Score Rather Than CHA ₂ DS ₂ DS ₂ -VASc?〕 Circulation, 2018, 138, 441-442.	1.6	0
172	Sleep apnea as an attributable risk for atrial fibrillation. International Journal of Cardiology, 2018, 264, 103.	1.7	0
173	Reponse to Qi et al. regarding the letter to the Editor "Development of Takotsubo syndrome and cancer may share a common signaling pathway― International Journal of Cardiology, 2018, 270, 79.	1.7	0
174	Letter by El-Battrawy et al Regarding Article, "Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe)― Circulation, 2018, 137, 2083-2084.	1.6	0
175	Delta CHA2DS2-VASc score as a predictor of stroke. Europace, 2019, 21, 179-179.	1.7	0
176	Letter by El-Battrawy et al Regarding Article, "Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis― Circulation, 2019, 139, 1344-1345.	1.6	0
177	Functional characterization of drug responses in induced pluripotent stem cell-derived cardiomyocytes from a short QT syndrome type 5 patient. Europace, 2021, 23, .	1.7	0
178	α1-adrenoceptors and takotsubo syndrome: pathophysiologic connotationsâ€"Authors' reply. Europace, 2021, 23, 1152-1152.	1.7	0
179	Effect of Anemia on the Prognosis of Patients with Ventricular Tachyarrhythmias. American Journal of Cardiology, 2021, 154, 54-62.	1.6	0
180	Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent. Journal of Geriatric Cardiology, 2019, 16, 840-843.	0.2	0

#	Article	IF	CITATIONS
181	Discriminating factors excluding patients from a catheter-based left atrial appendage closure and anÂoutcome analysis ofÂnon-intervened and intervened patients. Archives of Medical Science, 2020, , .	0.9	O
182	Glucose Counteracts Isoprenaline Effects on Ion Channel Functions in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Journal of Cardiovascular Development and Disease, 2022, 9, 76.	1.6	O
183	Cardiac disease and prognosis associated with ventricular tachyarrhythmias in young adults and adults. BMC Cardiovascular Disorders, 2022, 22, 136.	1.7	O
184	230â€f Antiplatelet therapy and outcome in COVID-19. Results from a multi-centre international prospective registry (HOPE-COVID). European Heart Journal Supplements, 2021, 23, .	0.1	0
185	123â€fProphylactic anticoagulation and aspirin therapy for hospitalized patients with COVID-19: a propensity score-matched analysis of the hope-COVID-19 registry. European Heart Journal Supplements, 2021, 23, .	0.1	O
186	Kidney Failure among Patients with Takotsubo Syndrome or Myocardial Infarction: A Retrospective Analysis. Journal of Cardiovascular Development and Disease, 2022, 9, 186.	1.6	0